Struggling in the wake of the discontinuation of ziritaxestat, Belgian biotech Galapagos (Euronext: GLPG) is to undertake a radical restructuring aimed at jump-starting the business.
New chief executive and erstwhile Johnson & Johnson (NYSE: JNJ) heavyweight Paul Stoffels has a challenge on his hands, with the firm’s stock price sliding and an alliance with Gilead Sciences (Nasdaq: GILD) faltering.
Outlining a new “Forward, Faster” strategy, the company said it would fire 200 people in Europe and invest more in new capabilities and programs in oncology.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze